

1 **Insights into the stability of a therapeutic antibody Fab**  
2 **fragment by molecular dynamics and its stabilization by**  
3 **computational design**

4 **Computational stabilization of an antibody Fab fragment**

5

6 **Nuria Codina<sup>1</sup>, Cheng Zhang<sup>1</sup>, Nesrine Chakroun<sup>1</sup> and Paul A. Dalby<sup>1</sup>**

7

8

9 <sup>1</sup>Department of Biochemical Engineering, University College London, Gordon Street, London,  
10 WC1E 7JE, UK

11

12

13 **Corresponding Author:**

14 Prof. Paul A. Dalby, Department of Biochemical Engineering, University College London,

15 Gordon Street, London, WC1E 7JE, UK. Tel: +44-20-7679-9566. Email: [p.dalby@ucl.ac.uk](mailto:p.dalby@ucl.ac.uk).

16

17

18

19

20

21

## 22 **Abstract**

23           Successful development of protein therapeutics depends critically on achieving stability  
24 under a range of conditions, while retaining their specific mode of action. Gaining a deeper  
25 understanding of the drivers of instability across different stress conditions, will potentially enable  
26 the engineering of protein scaffolds that are inherently manufacturable and stable. Here, we  
27 compared the structural robustness of a humanized antibody fragment (Fab) A33 using atomistic  
28 molecular dynamics simulations under two different stresses of low pH and high temperature.  
29 RMSD calculations, structural alignments and contact analysis revealed that low pH unfolding  
30 was initiated through loss of contacts at the constant domain interface ( $C_L$ - $C_H1$ ), prior to  $C_L$  domain  
31 unfolding. By contrast, thermal unfolding began with loss of contacts in both the  $C_L$ - $C_H1$  and  
32 variable domain interface ( $V_L$ - $V_H$ ), followed by domain unfolding of  $C_L$  and also of  $V_H$ , thus  
33 revealing divergent unfolding pathways. FoldX and Rosetta both agreed that mutations at the  $C_L$ -  
34  $C_H1$  interface have the greatest potential for increasing the stability of Fab A33. Additionally,  
35 packing density calculations found these residues to be under-packed relative to other inter-  
36 domain residues. Two salt bridges were identified that possibly drive the conformational change  
37 at low pH, while at high temperature, salt bridges were lost and reformed quickly, and not always  
38 with the same partner, thus contributing to an overall destabilization. Sequence entropy analysis  
39 of existing Fab sequences revealed considerable scope for further engineering, where certain  
40 natural mutations agreed with FoldX and Rosetta predictions. Lastly, the unfolding events at the  
41 two stress conditions exposed different predicted aggregation-prone regions (APR), which would  
42 potentially lead to different aggregation mechanisms. Overall, our results identified the early  
43 stages of unfolding and stability-limiting regions of Fab A33, which provide interesting targets for  
44 future protein engineering work aimed at stabilizing to both thermal and pH-stresses  
45 simultaneously.

46

47 **Author Summary**

48

49           Currently, antibody-based products are the most rapidly growing class of pharmaceuticals  
50 due to their high specificity towards their targets, such as biomarkers on the surface of cancer  
51 cells. However, they tend to aggregate at all stages of product development, which leads to  
52 decreased efficiency and could elicit an immunological response. Improvements in the stability of  
53 therapeutic antibodies are generally made during the development phase, by trial and error of the  
54 composition of the formulated product, which is both costly and time consuming. There is great  
55 demand and potential for identifying the drivers of instability across different stress conditions,  
56 early in the discovery phase, which will enable the rational engineering of protein scaffolds. This  
57 work elucidated the stability-limiting regions of the antibody fragment Fab A33 using several  
58 computational tools: atomistic molecular dynamics simulations, *in-silico* mutational analysis by  
59 FoldX and Rosetta, packing density calculators, analysis of existing Fab sequences and  
60 predictors of aggregation-prone regions. Results identified particular regions in which  
61 mutagenesis has the potential to stabilize Fab against both thermal and pH-stresses  
62 simultaneously. Overall, the methodology used here could improve the developability screening  
63 of candidate antibody products for many diseases, such as cancer, chronic inflammatory diseases  
64 and infectious diseases.

65

66 **Key Words**

67 Antibody fragment; protein stability; protein aggregation; protein engineering; molecular  
68 dynamics simulations

69

70

## 71 **Introduction**

72           In the last 30 years, monoclonal antibody products have become the main drug class for  
73 new approvals in the pharmaceutical industry [1]. To date, over 60 antibody-based drugs are on  
74 the market, representing half of the total sales, with over 550 further antibodies in clinical  
75 development [2]. They are used as therapeutic drugs to treat human diseases, mainly in oncology,  
76 auto-immune diseases and cardiovascular diseases. The use of antibody fragments, such as the  
77 antigen-binding antibody fragment (Fab) studied here, brings additional advantages, including  
78 deeper tissue penetration due to their smaller size, which has proven beneficial to treat tumors  
79 [3]. In addition, Fab fragments lack the Fc domain, and thus are not glycosylated which allows  
80 simpler and less costly manufacture due to their expression in prokaryotic systems [4]. However,  
81 the lack of the Fc domain leads to their more rapid clearance in humans than for full antibodies.

82           The stabilization of therapeutic proteins against aggregation remains one of the biggest  
83 challenges facing approvals as biopharmaceutical products [5–7]. Thus, not only their mode of  
84 action, but protein stability is a crucial factor to their becoming successful products. Novel  
85 antibody products such as Fabs, single-chain variable fragments (ScFvs) and bi-specifics are  
86 currently being developed and their properties remain largely unknown. Knowledge about the  
87 stability of these pharmaceutical products, especially in the early development stages, would aid  
88 in their engineering and the design of antibody fragments that are more aggregation resistant.

89           Native protein conformations are only marginally stable, and are highly dynamic, hence  
90 they are more realistically described as a native ensemble. There is increasing evidence to  
91 suggest that under native conditions, aggregation takes place primarily from partially unfolded  
92 native-like states [8–12]. However, little is known about the structures of native conformers that  
93 initiate aggregation, or how these are affected by different stress conditions. Local unfolding of  
94 proteins can expose aggregation prone-regions (APR), that have the potential to trigger  
95 aggregation [13,14]. APRs are the regions in the protein most likely to form and stabilize the cross-

96  $\beta$  structures that are characteristic of many aggregates, notably hydrophobic sequences with low  
97 net charge and a strong  $\beta$ -sheet forming propensity. Generally, APRs are located in the protein  
98 core, protected from the solvent, and thus blocked from forming cross- $\beta$  structure. Under certain  
99 stresses, such as an increase in temperature, a change in pH, addition of denaturants, or elevated  
100 shear force, structural regions in the protein may destabilize and partially unfold to expose any  
101 underlying APRs [15]. Each structural region of the protein can respond differently to stress, and  
102 so the overall pattern of responses is likely to vary with each type of stress. Thus, determining the  
103 conformational changes that a protein experiences under different stress conditions is important  
104 for identifying common routes towards stabilization across all stress conditions via either  
105 mutagenesis or formulation.

106 Molecular dynamics (MD) simulations have been extensively used to study protein stability  
107 [16–21]. MD simulations offer atomic resolution insights into the early conformational events that  
108 can take place under different conditions. To date, not many all-atom MD studies on antibody  
109 fragments have been reported. MD simulations were used previously to study the aggregation  
110 potential of an antibody Fab fragment, from a human IgG1k antibody, via multiple elevated  
111 temperature MD simulations at 300 K, 450 K and 500 K [22]. This revealed that domain interfaces  
112 deformed prior to the unfolding of individual domains, and that two  $V_H$  domain sites were  
113 potentially labile to aggregation. Their structural deformation increased the solvent-accessible  
114 surface area of the APRs in those regions. The unfolding process of an antibody Fab fragment  
115 was also studied using an elastic network model, to reveal that the constant regions were more  
116 flexible, and unfolded earlier, than the variable regions [23]. MD simulations at 450 K and 500 K  
117 have also revealed the stability-limiting regions of an antibody single-chain variable fragment  
118 (scFv) [24]. Disruption of the  $V_L$ - $V_H$  interface was found to precede the unfolding of the domain  
119 structures. In contrast to the study on the Fab above, the  $V_H$  domain of the scFv was found to be  
120 more thermally resistant than the  $V_L$  domain.

121 Each Fab is composed of one light and one heavy chain (Fig 1 and Fig S1), each

122 comprising a variable ( $V_L$  or  $V_H$ ) and a constant ( $C_L$  or  $C_H1$ ) domain. Each domain forms an  
123 immunoglobulin fold, having two layers of  $\beta$ -sheets, an inner  $\beta$ -sheet and an outer  $\beta$ -sheet.  
124 Constant domains are formed of seven  $\beta$ -strands in a 4+3 arrangement, while variable domains  
125 have two additional  $\beta$ -strands in a 5+4 arrangement. The variable domains contain the antigen-  
126 binding site at their complementary determining regions (CDRs), formed by three loops in  $V_L$  and  
127 three loops in  $C_L$ . There are five disulfide bonds in Fab, four of them intra-domain and the last one  
128 between the light and heavy chains at the hinge region. Individual domains interact to form the  
129 variable region interface ( $V_L$ - $V_H$ ), and the constant region interface ( $C_L$ - $C_H1$ ). Interface contacts  
130 are shown in Fig 1 and the residues involved in the contacts are listed in Table S1. The variable  
131 region interface is mainly formed by aromatic side chains that are tightly packed and located at  
132 the center of the interface (six Tyr, two Trp, and two Phe), forming hydrophobic interactions.  
133 However, fewer aromatic side-chains are involved in the constant region domain interface (four  
134 Phe). Furthermore, no contacts at  $<3.5$  Å were found between part of one of the  $\beta$ -strands (at  
135 residues 177-180) in the  $C_L$  domain, and the  $C_H$  domain in our Fab A33 homology model (Fig 1).

136  
137 **Fig 1. Fab A33 structure with interface contacts highlighted.** Fab is composed of light  
138 (magenta) and heavy (yellow) chains. Each chain contains variable ( $V_L$  and  $V_H$ ) and constant ( $C_L$   
139 and  $C_H1$ ) domains. The antigen-binding region at the complementary determining regions (CDRs;  
140 blue), are located in the variable domains. There are five disulfide bonds (gray highlights).  
141 Contacts between heavy and light chains within  $3.5$  Å are indicated with green dashed arrows.  $\beta$   
142 -strand 177-180 in  $C_L$  domain does not have contacts with  $C_H$  domain, zoom in right-inset.

143  
144 Here, we compare the early unfolding events of Fab A33 at both high temperature and  
145 low pH, using all-atom MD simulations. A common feature to both stress conditions was that  
146 unfolding was initiated by the loss of interfacial contacts between neighboring domains, and that  
147 domain unfolding occurred later. However, our results revealed different unfolding pathways for

148 the two stress conditions, leading to partial unfolding of only the C<sub>L</sub> domain at low pH, compared  
149 to destabilization of both C<sub>L</sub> and V<sub>H</sub> domains in the high temperature condition. These  
150 conformational changes exposed different predicted aggregation-prone regions (APR), which  
151 would additionally support divergent aggregation mechanisms. Salt-bridge analysis provided  
152 insights into the location of those that were broken most rapidly due to protonation in the low pH  
153 simulation, and also showed that high temperature led to an increased fluctuation of salt bridge  
154 formation and breaking, more generally throughout the structure. An *in-silico* mutational analysis  
155 by both FoldX and Rosetta, predicted that the constant domain interface had the greatest potential  
156 for further stabilization, a finding that was also supported by lower packing-density calculations.  
157 Taken together, our results determined the stability-limiting regions at low pH and high  
158 temperature for Fab A33, and also identified those with the greatest potential for mutations that  
159 simultaneously improve stability under both low pH and high temperature conditions.

160

## 161 **Results**

### 162 **Interface contacts, RMSD of individual domains and structural alignments revealed** 163 **different unfolding pathways at low pH and high temperature**

164 To determine which domains of Fab A33 are more susceptible to unfolding under low pH  
165 and high temperature, we first followed the RMSD of each individual domain (V<sub>L</sub>, V<sub>H</sub>, C<sub>L</sub> and C<sub>H1</sub>)  
166 along the simulations, as changes in RMSD are indicative of a conformational change.  
167 Simulations in the unfolding trajectories (pH 3.5 and pH 4.5 at 300 K, for low pH; pH 7.0 at 340 K  
168 and 380 K, for high temperature) were compared to the simulations in the native trajectory (pH  
169 7.0 at 300 K). For every condition of pH and temperature, three independent simulations were  
170 performed, and their average RMSD are shown in Figures 2 and 3. Additionally, structures from  
171 the unfolding trajectories (pH 3.5, for low pH; 380 K, for high temperature) were aligned to  
172 structures from the native trajectory (pH 7.0 at 300 K), to visualize the structural changes that  
173 individual domains experienced. For each domain alignment, ten structures were taken every 3 ns

174 from each simulation repeat, from the 20-50 ns range at which the RMSD had stabilized. Thus,  
175 a total of thirty structures from each stress condition were compared to thirty from the native  
176 trajectory. We also monitored the number of interface contacts between domains ( $V_L$ - $V_H$  and  $C_L$ -  
177  $C_H1$ ) during the simulations using a cutoff of 4 Å, to understand the temporal relationship between  
178 breakage of contacts in each interface, and the unfolding of each domain. The RMSD and radius  
179 of gyration ( $R_g$ ) of the whole protein are also shown at every condition in Fig S2; where increased  
180 RMSD and  $R_g$  were observed at the conditions of low pH (3.5) and high temperature (380 K).

181 At low pH, almost no change was observed in the number of interfacial contacts within the  
182 variable region ( $V_L$ - $V_H$ ) of Fab A33, when compared to at pH 7.0. For pH 7.0,  $333 \pm 24$  contacts  
183 were maintained (discarding the first frame), and  $309 \pm 24$  contacts were maintained at pH 3.5  
184 (Fig 2A). By contrast, a loss of interfacial contacts in the constant region ( $C_L$ - $C_H1$ ) was observed  
185 between pH 7.0 with  $335 \pm 17$  contacts, and pH 3.5 with  $265 \pm 12$  contacts (Fig 2B). Interestingly,  
186 this loss of constant region interfacial contacts at low pH took place very quickly, with pH 7.0  
187 retaining  $384 \pm 14$  contacts after 5 ns of the simulation, while simulations at pH 3.5 retained only  
188  $270 \pm 11$  contacts. This could be attributed to the lack of a well-defined hydrophobic core in the  
189  $C_L$ - $C_H1$  interface, resulting in numerous early-disrupted contacts. Notably,  $C_L$  was the only domain  
190 to show a noticeable conformational change at low pH, revealed as an increase in RMSD from  
191  $1.8 \pm 0.1$  Å at pH 7.0 (calculated between 20-50 ns of the simulation), to  $2.2 \pm 0.1$  Å at pH 3.5  
192 (Fig 2E). This domain displacement occurred in the first 20 ns, after many interface contacts had  
193 already been lost with respect to pH 7.0, which suggests that destabilization of the  $C_L$ - $C_H1$   
194 interface preceded and potentially accelerated the unfolding of the  $C_L$  domain. The other domains  
195 ( $V_L$ ,  $V_H$  and  $C_H1$ ) did not unfold significantly during the low pH simulations (Fig 2C, 2G and 2I).  
196 Structural alignments confirmed this result, showing remarkably good alignment between the pH  
197 7.0 and pH 3.5 structures in each case for  $V_L$ ,  $V_H$  and  $C_H1$  (Fig 2D, 2H and 2J). Alignments of the  
198  $C_L$  domain at pH 7.0 and pH 3.5 revealed a slight displacement at low pH, especially visible in the  
199 loop regions (Fig 2F). These findings agreed with previous experimental work, which combined



200 SAXS, atomistic modelling and smFRET to reveal the displacement of the C<sub>L</sub> domain in Fab A33  
201 at low pH [14].

202  
203 **Fig 2. Interface contacts, RMSD of individual domains and structural alignments for**  
204 **simulations at pH 7.0, 4.5 and 3.5 (all 300 K).** A, B) Contacts between light and heavy chains  
205 within 4.0 Å with simulation time, for variable (V<sub>L</sub>-V<sub>H</sub>) and constant (C<sub>L</sub>-C<sub>H</sub>) regions, respectively,  
206 pH values as labelled. C, E, G, I) RMSD of individual domains with simulation time for V<sub>L</sub>, V<sub>H</sub>, C<sub>L</sub>  
207 and C<sub>H</sub>1, respectively, pH values as labelled. In all cases, the average of three independent  
208 simulations is shown with the SEM as error. D, F, H, J) Alignments of structures from simulations  
209 at pH 7.0 and 3.5 for V<sub>L</sub>, V<sub>H</sub>, C<sub>L</sub> and C<sub>H</sub>1, respectively. Ten structures from the last 30 ns of each  
210 simulation were used, totaling thirty structures from pH 7.0 and thirty from pH 3.5.

211  
212 For thermal denaturation, MD simulations are commonly run at temperatures as high as  
213 500 K to attempt to fully denature the protein. Here, we aimed to capture the early thermal  
214 unfolding events of Fab A33, which involve only partial unfolding of the protein. For this reason,  
215 and to reflect experimental conditions more closely, lower temperatures of 340 K and 380 K were  
216 used in our simulations. Interfacial contacts were found to break across both the variable and the  
217 constant regions (Fig 3A and 3B). At 380 K, there was an average of only  $220 \pm 24$  contacts in  
218 the variable interface and  $204 \pm 13$  contacts in the constant interface. Those between the constant  
219 domains broke earlier than those of the variable domains, with only  $218 \pm 14$  present after just 5  
220 ns of the simulations at 380 K. This is consistent with previous reports, which also found that the  
221 constant region interface lost a larger fraction of its total interface contacts consistently faster than  
222 the variable region interface at high temperature, and also that domain unfolding occurred later  
223 than the loss of interfacial contacts [22]. Overall, more contacts were lost at both interfaces with  
224 high temperature than at low pH.

225 While  $V_L$  and  $C_{H1}$  experienced only small domain displacements (Fig 3C and 3I), clear  
226 domain unfolding was observed for both  $C_L$  and  $V_H$  (Fig 3E and 3G). At 380 K from 20 ns to 50 ns,  
227 the  $V_H$  domain displayed an increase in RMSD from 2.4 Å at pH 7.0, to 3.2 Å at pH 3.5. That for  
228 the  $C_L$  domain increased from 1.8 Å at pH 7.0 to 2.4 Å at pH 3.5 (all averages were  $\pm 0.1$  Å). In  
229 these cases, many interface contacts were also lost with respect to pH 7.0 and 300 K, before the  
230 unfolding of individual structural domains, again consistent with destabilization of the interface  
231 contributing to the loss of stability for the individual domains. For both  $V_L$  and  $C_{H1}$ , structures from  
232 the simulations at 300 K and 380 K aligned well (Fig 3D and 3J), whereas for  $V_H$  and  $C_L$  (Fig 3H  
233 and 3F) the domains were structurally perturbed at the higher temperature. The  $V_H$  domain  
234 experienced a displacement of the loops on the N-terminal region, including the three CDR loops  
235 (Fig 3H). Differences in the  $C_L$  domain at high temperature were found in the loops and within an  
236 internal  $\beta$ -strand (Fig 3F). This was consistent with previous work which identified instability and  
237 structural changes in the  $V_H$  domain of another Fab at high temperature [22]. Taken together,  
238 these findings suggest a different unfolding pathway for Fab A33 at low pH and at high  
239 temperature.

240

241 **Fig 3. Interface contacts, RMSD of individual domains and structural alignments for**  
242 **simulations at pH 7.0 and temperatures 300 K, 340 K and 380 K.** A, B) Contacts between light  
243 and heavy chains within 4.0 Å with simulation time, for variable ( $V_L$ - $V_H$ ) and constant ( $C_L$ - $C_H$ )  
244 regions, respectively, temperature values as labelled. C, E, G, I) RMSD of individual domains with  
245 simulation time for  $V_L$ ,  $V_H$ ,  $C_L$  and  $C_{H1}$ , respectively, temperature values as labelled. In all cases,  
246 the average of three independent simulations is shown with the SEM as error. D, F, H, J)  
247 Alignments of structures from simulations at temperatures of 300 K and 380 K for  $V_L$ ,  $V_H$ ,  $C_L$  and  
248  $C_{H1}$ , respectively. Ten structures from the last 30 ns of each simulation were used, totaling thirty  
249 structures from 300 K and thirty from 380 K.

250

251 **Loss in  $\beta$ -strand secondary structure confirms regions of unfolding**

252 The unfolding of individual domains was additionally followed by their loss in secondary  
253 structure (SS); specifically, we monitored the change in  $\beta$ -strand structure. Constant domains are  
254 composed of seven  $\beta$ -strands named A to G, while variable domains contain two more strands, a  
255 total of nine, with the two additional strands termed C' and C" (Fig 4A and 4B). To calculate the  
256 loss in  $\beta$ -strand structure for each of the strands, we first tracked the secondary structure  
257 designation for each residue in Fab A33 throughout the simulations (Fig S3). The percentage of  
258 time occupied within  $\beta$ -strand was calculated for each residue, and then summed for each of the  
259 32  $\beta$ -strands in Fab A33. This value was averaged for each of the three repeats at each condition.  
260 The percentage change in  $\beta$ -strand occupancy was then calculated, to determine the loss relative  
261 to the reference simulations at pH 7, 300 K (Fig 4 and Fig S4).

262

263 **Fig 4. Loss of secondary structure for each of the 32  $\beta$ -strands of Fab A33.** A, B) Strand  
264 order shown by lettering (A-G) for variable and constant domains, respectively. C, D) Percentage  
265 increase/decrease in  $\beta$ -strand secondary structure for each strand in Fab during the simulations,  
266 respect to pH 7.0 and 300 K, for: C) pH 3.5 and 300 K, D) pH 7.0 and 380 K. Error bars are the  
267 same and equal for positive and negative values.

268

269 At pH 3.5, the C<sub>L</sub> domain had an overall loss in secondary structure content, confirming  
270 the results found in the previous section (Fig 4C). Strands F (-13 ± 3 %) and G (-12 ± 7 %) of the  
271 C<sub>L</sub> domain showed the highest  $\beta$ -sheet structure loss, both located in the outer  $\beta$ -sheet. Strands  
272 B (-8 ± 6 %), C (-6 ± 4 %) and E (-8 ± 6 %) also experienced significant losses. Additionally, the  
273  $\beta$ -strand C" of the V<sub>L</sub> domain also showed a large variability between repeat trajectories. C" is the  
274 shortest strand, and is located at the extreme of the outer  $\beta$ -sheet connecting the CDR-2 loop,  
275 and so the large variability suggests that this is a flexible region prone to the loss of secondary  
276 structure in some but not all simulations.

277 At 380 K, the losses in  $\beta$ -strand content were located in both the  $C_L$  and  $V_H$  domains,  
278 consistent with the unfolding described in the previous section (Fig 4D). Many strands in the  $C_L$   
279 domain showed significant losses, A ( $-7 \pm 2 \%$ ), C ( $-8 \pm 3 \%$ ), D ( $-16 \pm 12 \%$ ) and G ( $-5 \pm 1 \%$ ),  
280 located at the extremes of the inner and outer  $\beta$ -sheets. The  $V_H$  domain also showed high losses  
281 of  $\beta$ -strand. However, of these strands A ( $-18 \pm 17 \%$ ) and G ( $-8 \pm 9 \%$ ) also showed high variability  
282 between repeats. Interestingly, these same two strands in  $V_H$  were previously found to deform at  
283 high temperature in a different Fab [22]. Strand C" ( $-13 \pm 4 \%$ ) of the  $V_H$  domain also showed a  
284 significant loss of  $\beta$ -strand content.

285

### 286 **Salt bridge analysis identifies key stabilizing salt bridges**

287 To identify the ionizable residues that potentially drive the conformational changes at low  
288 pH, a salt bridge analysis was performed. Salt bridges were identified over the simulation time for  
289 all the MD simulations carried out, using an O-N bond distance cutoff of 3.2 Å. From these, the  
290 occurrence (%) of each salt bridge during the simulation was calculated, and averaged for the  
291 three independent repeats at each condition. Lastly, the most persistent salt bridges at each  
292 condition were highlighted in the Fab A33 structure (Fig 5 and Fig S5).

293

294 **Fig 5. Salt bridge analysis.** A, B, C) Salt bridges formed during the simulation time for  
295 representative MD simulations at A) pH 7.0 and 300 K, B) pH 3.5 and 300 K and C) pH 7.0 and  
296 380 K. Presence of a salt bridge is indicated in white and absence in black. D, E, F) List of salt  
297 bridges and its occurrence for simulations at D) pH 7.0 and 300 K, E) pH 3.5 and 300 K and F)  
298 pH 7.0 and 380 K. Values shown are the average of three independent simulations with their SEM  
299 as error. The more persistent salt bridges are highlighted for pH 7.0 (green), pH 3.5 (red) and pH  
300 7.0 and 380 K (blue). G, H, I) The more persistent salt bridges are mapped into the Fab A33  
301 structure. Two key stabilising salt bridges (Glu165-Lys103 and Glu195-Lys149) are highlighted in  
302 a dashed circle.

303

304 At pH 7.0 and 300 K, a total of 36 salt bridges were present. Interestingly, many of these  
305 salt bridges were flexible and able to form with different partners during a single trajectory, such  
306 as Asp122 which partnered with both Lys126 and Lys436, or Asp304 which paired with both  
307 Arg252 and Arg281. This is consistent with previous work, which found that salt bridges break  
308 and reform, and not always with the same partner [25]. The most persistent (as % of time present)  
309 salt bridges at pH 7.0 were Glu165-Lys103 ( $67 \pm 4$  %), Glu195-Lys149 ( $65 \pm 4$  %), Asp82-Arg61  
310 ( $61 \pm 14$  %), Asp151-His189 ( $58 \pm 24$  %), and Asp304-Arg252 ( $55 \pm 27$  %), as shown in Fig 5A,  
311 5D and 5G.

312 At low pH, pH 3.5, 300 K, a total of 27 salt bridges were observed, but most of them were  
313 very short lived. The more persistent salt bridges at pH 3.5 were Asp151-His189 ( $86 \pm 6$  %),  
314 Asp82-Arg61 ( $78 \pm 11$  %), Asp122-Lys126 ( $73 \pm 1$  %), Asp362-Lys335 ( $56 \pm 6$  %) (Fig 5B, 5E  
315 and 5H). The protonation state at the end of the pH 3.5 simulations was calculated again using  
316 these Fab conformations, which revealed these salt bridges to be still present due to predicted  
317  $pK_a$  values of below 3.5 for these aspartates. Comparison of the salt bridges at pH 7.0 and 3.5,  
318 indicated the presence of two salt bridges that potentially trigger the conformational change  
319 observed at low pH, and thus the loss of Fab A33 stability. Glu165-Lys103 and Glu195-Lys149,  
320 were the most persistent contacts at pH 7.0, but were not present at pH 3.5. Glu165-Lys103  
321 bridges the  $C_L$  domain to the  $V_L$  domain, and Glu195-Lys149 bridges the outer  $\beta$ -strands C and  
322 F of the  $C_L$  domain. Loss of these salt bridges at low pH, would therefore destabilize the  $C_L$   
323 domain, and promote the observed  $C_L$  domain displacement.

324 At high temperature, pH 7.0 and 380 K, a total of 45 salt bridges were observed. The  
325 greater number than at 300 K, reflects an increased conformational flexibility of many salt bridges  
326 at the higher temperature, in which they often broke, but then reformed with a different partner.  
327 Indeed, at the high temperature, salt bridges broke and reformed much faster (Fig 5C). At 380 K,  
328 the total time present for the most persistent salt bridges observed at 300 K, had decreased to 47

329  $\pm 9$  % for Glu165–Lys103,  $58 \pm 3$  % for Glu195-Lys149,  $21 \pm 7$  % for Asp151-His189, and  $43 \pm$   
330  $22$  % for Asp304-Arg252. However, Asp82-Arg61 increased in occurrence to  $70 \pm 3$  % (Fig 5C,  
331 5F and 5I). These findings indicate that the increased dynamics at high temperature, results in  
332 constant rupture and formation of salt bridges, and this transient disruption leaves Fab A33 more  
333 susceptible to unfolding.

334

### 335 **FoldX, Rosetta and packing density calculations predict sub-optimal stability of C<sub>L</sub> and the** 336 **C<sub>L</sub>-C<sub>H</sub>1 interface**

337 Computational tools such as FoldX and Rosetta-ddG [26,27] predict the relative changes  
338 in folding free energy ( $\Delta\Delta G$ ) between the Gibbs free energies ( $\Delta G$ ) of the protein carrying a  
339 simulated point mutation and the wild-type protein, to find those mutations that will most  
340 significantly reduce the free energy of the protein. These approaches are often also combined to  
341 find consensus predictions [28,29]. To predict stabilizing mutations in Fab A33, we calculated the  
342  $\Delta\Delta G$  with both FoldX and Rosetta-ddG, of all possible single-mutant variants when accessing all  
343 19 other substitutions across the 442 residue positions in Fab A33, totaling 8398 mutations. FoldX  
344 identified 1879 of these mutations as stabilizing (22.4 %), while Rosetta-ddG identified 2386 (28.4  
345 %). Of these, 956 (11.4 %) were predicted by both algorithms. Fig S6 shows the correlation  
346 between the mutations predicted by FoldX and Rosetta, and Table S2 lists the 25 most stabilizing  
347 mutations predicted by both algorithms, with their respective  $\Delta\Delta G$  values.

348 Fig 6A compares the greatest stabilization predicted by FoldX and Rosetta, at each of the  
349 442 residues in Fab A33, regardless of the specific mutation selected by each algorithm. Six  
350 residues were highlighted in magenta in Fig 6A and 6B, as those predicted by both algorithms to  
351 have the greatest potential for stabilization. These residues corresponded to S176, N137, S397,  
352 S159, S12 and T180, and all of their mutations predicted to be most stabilizing, were to more  
353 hydrophobic amino acids, such as Trp, Leu, Ile, Phe and Tyr (Fig S6 and Table S2). Four of the  
354 six residues (S176, N137, S397 and T180), are located in the constant domain interface, between

355 C<sub>L</sub> and C<sub>H1</sub> domains (Fig 6B), suggesting significant potential for further stabilization within the  
356 C<sub>L</sub>-C<sub>H1</sub> interface. Furthermore, S159 is in the C<sub>L</sub> domain, but interacts with an outer β-strands of  
357 C<sub>L</sub>, and S12 is in the V<sub>L</sub> domain, but interacts with the C<sub>L</sub> domain (Fig 6B). Thus overall, the C<sub>L</sub>  
358 domain has a relatively high potential for stabilization, through repacking of the C<sub>L</sub>-C<sub>H1</sub> interface,  
359 within the C<sub>L</sub> domain itself, and also through improved interaction between C<sub>L</sub> and V<sub>L</sub>. This is  
360 consistent with the MD simulations which found the displacement of C<sub>L</sub> away from the interface  
361 with C<sub>H</sub>, and subsequent unfolding of the C<sub>L</sub> domain, to be critical steps in early or partial  
362 unfolding.

363 Further highly stabilizing mutations at residues S395 and S267, as predicted only by  
364 FoldX, are highlighted in green in Fig 6. S395 is also located in the C<sub>L</sub>-C<sub>H1</sub> interface. However,  
365 S267 is in CDR2 of the V<sub>H</sub> domain, and so not a good candidate for general framework  
366 stabilization due to its role in antigen binding. Highly stabilizing mutations at residues K103 and  
367 T72, as predicted only by Rosetta-ddG are highlighted in yellow. These were both located in the  
368 V<sub>L</sub> domain, but K103 also interacts with the C<sub>L</sub> domain, further suggesting that the interactions  
369 within and around the C<sub>L</sub> domain are the least optimized for stability.

370  
371 **Fig 6. Predicted residues that can be stabilized further by FoldX and Rosetta-ddG.** A)  
372 Correlation between FoldX and Rosetta predictions. Residues predicted by both software to be  
373 most stabilizing are shown in magenta on the bottom left. Residues predicted only by FoldX to be  
374 stabilizing are shown in green and mutations predicted only by Rosetta in yellow. B) Residues  
375 predicted to be stabilized further the most are mapped in Fab A33 structure, following the same  
376 colour scheme as in A).

377  
378 The packing density of each Fab A33 residue was calculated using the package occluded  
379 surface (OS) software, which calculates occluded surface and atomic packing [30,31]. The  
380 occluded surface packing (OSP) value of each atom is calculated from normal vectors that extend

381 outward from the atom surface until they intersect a neighboring van der Waals surface (Fig S7).  
382 This value is 0.0 for completely exposed residues and 1.0 where 100% of molecular surface is in  
383 contact with other van der Waals surface. The average OSP for all 28  $\beta$ -strand residues within  
384 domain interfaces ( $V_L$ - $V_H$  and  $C_L$ - $C_H1$ ) was  $0.49 \pm 0.01$  (OSP values shown in Table S3). By  
385 contrast, the average OSP of the five constant-domain interface residues (S176, N137, S397,  
386 T180, and S395), identified by FoldX and Rosetta as having high stabilization potential, was  $0.41$   
387  $\pm 0.05$  (OSP values shown in Table S3). This can be visualized in Fig 7, where OSP values were  
388 mapped in the structure of Fab A33, with red to indicate high packing density, and blue to indicate  
389 low packing density.  $\beta$ -strand residues within domain interfaces were highlighted as sticks (Fig  
390 7A). Residues in the constant interface ( $C_L$ - $C_H1$ ) were lighter colored than residues in the variable  
391 interface ( $V_L$ - $V_H$ ), indicating less tight packing of the constant interface. An insight of the residues  
392 identified by FoldX and Rosetta is provided in Fig 7B, where a lighter color than the residues in  
393 the variable interface was also observed. This result shows that the predicted residues are under-  
394 packed, and therefore have the potential to be mutated to pack the  $C_L$ - $C_H1$  interface more tightly.  
395

396 **Fig 7. Packing density of every residue in Fab A33, computed using Occluded Surface. A)**  
397 The occluded surface packing (OSP) values were added as B-factors to the PDB file for the Fab  
398 A33 homology model. High packing values are shown in red and low values in blue. Residues in  
399  $\beta$ -strands within domain interfaces ( $V_L$ - $V_H$  and  $C_L$ - $C_H1$ ) are highlighted in sticks and ball  
400 representation. B) Residues identified by FoldX and Rosetta that could be stabilised further (S176,  
401 N137, S397, T180, and S395) are highlighted in sticks and ball, and sphere representation.

402

### 403 **Comparison to natural sequence variations in Fabs**

404 The natural variability of Fab sequences was identified from within one hundred light  
405 chains and one hundred heavy chains curated from those available in the Protein Data Bank [32].  
406 Sequence alignment and sequence entropy calculations for each residue were obtained using



407 Bioedit [33]. An entropy of zero indicates a fully conserved residue, whereas 3.04 is the maximum  
408 entropy, originating from 21 possibilities (all amino acids plus the stop codon). There is significant  
409 positional bias in the sequence variability of Fabs due to the hypervariability of the CDRs [34], the  
410 presence of kappa ( $\kappa$ ) and lambda ( $\lambda$ ) light chain isotypes, allotypic diversity across individuals,  
411 and idiotypic variability within the variable domains of individuals. The sequence entropy analysis  
412 (Fig S8) clearly shows this, with the highest sequence entropy ( $>2$ ), for the six CDRs, and a  
413 slightly lower variability on average within the C<sub>H</sub> domain. Similarly, the higher sequence entropy  
414 on average for the C<sub>L</sub> domain, compared to the C<sub>H</sub> domain results from the grouping of kappa ( $\kappa$ )  
415 and lambda ( $\lambda$ ) light chain isotypes.

416 Even though residues in the constant regions have more restricted variability, many  
417 natural variations are still observed that may affect stability. Except for the fully conserved S176,  
418 the sites predicted as having the most potential for stabilizing mutations by both FoldX and  
419 Rosetta, had natural variations, with sequence entropy values of N137: 0.74, S397: 0.15, S159:  
420 0.96, S12: 0.96, T180: 0.43. This was also true for mutations identified only by FoldX (S267: 1.69  
421 and S395: 0.69), and only by Rosetta-ddG (K103: 0.16, T72: 0.91). Comparisons between the  
422 existing mutations and the stabilizing mutations suggested by FoldX and Rosetta are shown in  
423 Table 1. In general, the mutations found in existing Fabs were conservative changes to residues  
424 with properties similar to the original residue. For instance, S397 and S395 are only naturally  
425 mutated to Thr, whereas T180 can also be Ser, and K103 can be Arg. By contrast, FoldX and  
426 Rosetta predictions were typically from polar to more hydrophobic residues, typically to Ile, Leu,  
427 Trp, Val, and Tyr. A few suggested mutations were also found naturally, such as N137I, S12Y,  
428 and S267P. S159 also shows the potential to be mutated to more hydrophobic residues, Val and  
429 Met. Overall, this analysis shows that despite their low natural variability, many residues in the  
430 constant domains had significant scope for stabilization through non-natural mutations.

431

432 **Table 1. Comparison between the mutations in existing human and mouse Fabs and the**  
 433 **stabilizing mutations suggested by FoldX and Rosetta.**

Original Residue	Light chain				Heavy Chain		Suggested mutation by FoldX and Rosetta
	Kappa ( $\kappa$ )		Lambda ( $\lambda$ )		Human	Mouse	
	Human	Mouse	Human	Mouse			
S176	-	-	-	-	N.A.	N.A.	W, M, R, L Y
N137	-	-	-	T, I	N.A.	N.A.	L, M, I
S397	N.A.	N.A.	N.A.	N.A.	-	T	I, L, W, V
S159	-	V	V	M	N.A.	N.A.	R, F
S12	-	Y, P, A, T	-	T	N.A.	N.A.	F, Q, Y
T180	-	-	S	-	N.A.	N.A.	Y, W
S395	N.A.	N.A.	N.A.	N.A.	-	T	L, M, R, I, V
S267	N.A.	N.A.	N.A.	N.A.	P, W, Y, T, G, D, N, A	P, I, G, N, D, Q, L	P
K103	R	-	-	-	N.A.	N.A.	Y, F, T
T72	S	S	S	A	N.A.	N.A.	Y

434 N.A. (Not Applicable), mutation does not apply to the chain (light or heavy); -, no existing  
 435 mutations were found on that chain.

436  
 437 **Solvent exposure of different aggregation-prone regions promotes different aggregation**  
 438 **pathways for low pH and high temperature**

439 The aggregation pathways of Fab A33 at low pH and high temperature at pH 7.0, are  
 440 already known to result in different aggregate morphologies [12]. Here we explored whether the

441 two conditions also exposed different aggregation-prone regions (APRs). APRs can be predicted  
442 from sequence information, and either assume a fully unfolded protein, or otherwise refine the  
443 prediction by factoring solvent exposure of the APR based on structure and dynamics information.  
444 The sequence-based predictions are based on either the intrinsic properties of amino acids, or  
445 their compatibility with protein structural features in known amyloid fibril structures. Examples of  
446 sequence-based predictors include PASTA 2.0 [35], TANGO [36], AGGRESCAN [37], MetAmyl  
447 [38], FoldAmyloid [39] and Waltz [40]. As the ability of APRs to trigger aggregation depends upon  
448 their solvent accessibility, more recent structure-based predictors consider the three-dimensional  
449 structure of the protein and in some cases also their potential modes of partial unfolding.  
450 Examples include AGGRESCAN 3D [41], AggScore [42], SAP [43] and Solubis [44]. Here, we  
451 want to compare the solvent accessibility of APRs in Fab A33, between our MD simulations at  
452 the unfolding conditions and at the reference trajectory. Thus, we used sequence-based APR  
453 predictors to determine the APRs in Fab A33, and then determined their solvent accessible  
454 surface area (SASA) from the MD simulations, for relative comparisons.

455 We used four sequence-based predictors to determine the APRs in Fab A33, PASTA 2.0,  
456 TANGO, AGGRESCAN and MetAmyl. APRs were selected when three out of the four predictors  
457 identified an aggregation-prone sequence (Fig S9A). Seven APRs were found, namely residues  
458 31-36, 47-51, 114-118 and 129-139 in the light chain and residues 261-165, 325-329 and 387-  
459 402 in the heavy chain. The presence of these APRs was confirmed using Amylpred2 [45], a  
460 consensus tool of eleven existing algorithms (Fig S9A). The location of the seven APRs revealed  
461 that they are all located in the interior of Fab A33, and thus protected from the solvent (Fig S9B).  
462 Exposure of one of these APRs as a result of a conformational change by an environmental  
463 stress, has the potential to trigger aggregation. Thus, the SASA of each APR during the  
464 simulations was calculated, as well as the difference in solvent accessibility,  $\Delta$ SASA, between  
465 unfolding conditions and the reference simulation (Table 2).

466 At low pH, only one APR (residues 387-402), was found to increase its solvent accessibility

467 significantly at pH 3.5, with an increase of  $57 \pm 25 \text{ \AA}^2$  (10 % increase) (Table 2), consistent with  
 468 previous experimental findings [14]. This APR is located in the  $C_H1$  domain and its exposure can  
 469 be explained by the  $C_L$  domain displacement observed at low pH (Fig 8A). At high temperature,  
 470 two APRs were found to increase their solvent accessibility, APR 261-265 located in  $V_H$  and APR  
 471 129-139 located in  $C_L$  (Fig 8B). APR 261-265 increased its SASA  $15 \pm 6 \text{ \AA}^2$  (107 % increase) and  
 472 APR 129-139 increased its SASA  $20 \pm 16 \text{ \AA}^2$  (13 % increase) (Table 2). The location of these  
 473 APRs agrees with the domains found to unfold previously at high temperature. Notably, the APRs  
 474 exposed at low pH and high temperature are different, suggesting the potential to follow different  
 475 aggregation mechanisms depending on the stress applied.

476

477 **Table 2. SASA of the APRs in Fab A33 during simulations and SASA differences between**  
 478 **unfolding simulations and the reference simulation.** Solvent accessible surface area of the  
 479 seven aggregation-prone regions in Fab A33 during all simulations, and relative differences  
 480 ( $\Delta$ SASA) between the unfolding trajectories (pH 3.5 and 4.5 at 300 K, for low pH; pH 7.0 at 340  
 481 K and 380 K, for high temperature) and the reference trajectory (pH 7.0 and 300 K).

APR	Fab domain	SASA	SASA	$\Delta$ SASA	SASA	$\Delta$ SASA	SASA	$\Delta$ SASA	SASA	$\Delta$ SASA
		( $\text{\AA}^2$ )	( $\text{\AA}^2$ )	( $\text{\AA}^2$ )	( $\text{\AA}^2$ )	( $\text{\AA}^2$ )	( $\text{\AA}^2$ )	( $\text{\AA}^2$ )	( $\text{\AA}^2$ )	( $\text{\AA}^2$ )
		pH 7.0 300 K	pH 4.5 300 K	pH(4.5- 7.0)	pH 3.5 300 K	pH(3.5- 7.0)	pH 7.0 340 K	T(340- 300 K)	pH 7.0 380 K	T(380 - 300 K)
31-36	$V_L$	$118 \pm 4$	$112 \pm 5$	$-5 \pm 7$	$115 \pm 16$	$-3 \pm 17$	$120 \pm 8$	$3 \pm 9$	$106 \pm 4$	$-12 \pm 6$
47-51	$V_L$	$100 \pm 1$	$104 \pm 7$	$4 \pm 13$	$115 \pm 20$	$15 \pm 23$	$101 \pm 6$	$1 \pm 13$	$96 \pm 7$	$-4 \pm 13$
114-118	$C_L$	$125 \pm 4$	$121 \pm 7$	$-4 \pm 8$	$110 \pm 7$	$-15 \pm 8$	$112 \pm 2$	$-13 \pm 5$	$120 \pm 13$	$-5 \pm 13$
129-139	$C_L$	$152 \pm 8$	$147 \pm 11$	$-5 \pm 13$	$151 \pm 12$	$0 \pm 14$	$165 \pm 10$	$13 \pm 13$	$172 \pm 14$	$20 \pm 16$

261-265	V <sub>H</sub>	14 ± 2	13 ± 0	-1 ± 2	13 ± 1	-1 ± 3	19 ± 1	5 ± 3	29 ± 5	15 ± 6
325-329	V <sub>H</sub>	122 ± 16	115 ± 14	-7 ± 21	119 ± 7	-3 ± 17	88 ± 10	-34 ± 19	120 ± 22	-1 ± 27
387-402	C <sub>H1</sub>	552 ± 21	547 ± 25	-5 ± 33	609 ± 12	57 ± 25	544 ± 7	-9 ± 22	489 ± 48	-15 ± 21

---

482

483

484 **Fig 8. Fab A33 predicted APRs that increase its solvent accessibility at low pH and high**

485 **temperature.** A) APR 387-402 increases its SASA at pH 3.5 and B) APR 261-265 and APR 129-

486 139 increase its SASA at 380 K (Table 1). All mapped in red in Fab A33 homology structure.

487

488

## 489 Discussion

490 Antibody-based products are the main class of approved biopharmaceuticals, due to their

491 high target specificity [1]. However, there are many barriers to their successful development into

492 therapeutics, with protein aggregation being perhaps the most common and challenging to

493 prevent [5]. There is a need to identify potential instabilities of therapeutic proteins during their

494 early development, particularly against stresses that they will encounter during manufacture,

495 storage and delivery. This would allow their early elimination from further development, or

496 otherwise rational mutagenesis into more stable products. In this context, we have elucidated the

497 first unfolding events that take place on a humanized Fab A33 using atomistic MD simulations,

498 and compared these to predictions of potentially stabilising mutations using computational tools.

499 Our simulations showed that contacts at the interface between domains (V<sub>L</sub>-V<sub>H</sub> and C<sub>L</sub>-

500 C<sub>H1</sub>) were lost before individual domains unfolded. Interfacial contacts in the constant domain

501 were the least stable, and were lost very quickly during the simulations under both stresses of low

502 pH and high temperature. In line with these results, FoldX and Rosetta agreed that the residues

503 that can be stabilized the most, are located in the constant domain interface. Further validation  
504 was provided by packing density calculations, which revealed that the residues identified by the  
505 stability predictors, were under packed relative to the other residues located in the interface  
506 between domains. Based on these findings, we speculate that improvement of Fab A33 stability  
507 should be targeted to the constant domain interface. Only one of the top mutations suggested by  
508 FoldX and Rosetta, N137I was found to be present in our analysis of natural variation within  
509 existing Fab sequences. However, there was significant scope for improvement through mutating  
510 the interfacial residues S176, N137, S397, T180, and S395, to the suggested hydrophobic  
511 residues.

512 The further goal could be to improve the stability of the individual domains. The C<sub>L</sub> domain  
513 was found to unfold at both, low pH and high temperature. Salt bridge analyses identified two key  
514 salt bridges at the heart of this domain unfolding at low pH, Glu165-Lys103 and Glu195-Lys149.  
515 Glu165-Lys103 bridges the C<sub>L</sub> domain to the V<sub>L</sub> domain, and Glu195-Lys149 is located in outer  
516 β-strands of the C<sub>L</sub> domain, bridging β-strands C and F. FoldX and Rosetta also identified  
517 stabilizing mutations in the C<sub>L</sub> domain. To stabilize the interaction between the C<sub>L</sub> and V<sub>L</sub> domain,  
518 hydrophobic mutants of S12 and K103 were predicted. Interestingly, the mutation S12 to Tyr is  
519 found naturally. In the C<sub>L</sub> domain, S159 was identified, which interacts with an outer β-strand,  
520 suggesting this interaction can also be improved. Lastly, the V<sub>H</sub> domain was also found to unfold  
521 at high temperature. The only mutation identified in this domain is S267, to a Pro, which notably  
522 is found naturally. Overall, the results found with MD simulations and stabilizing software  
523 predictors strongly agree in the domains of Fab A33 that can be stabilized further.

524 In order to gain insights into the mechanisms by which aggregation might occur, APRs in  
525 Fab A33 were identified, and their solvent accessibilities were compared. All APRs in Fab A33  
526 are located in the interior of the protein, however, at low pH and high temperature the SASA of  
527 certain APRs increased. Notably, different APRs were exposed under both stresses, suggesting  
528 that different aggregation mechanisms occur under each stress. This result stresses the

529 importance of identifying the stability of a protein under the different stresses it might encounter.  
530 Taken together, this work provides insights into the stability and robustness of the therapeutically  
531 relevant Fab A33, and offers a path to the engineering and design of a more aggregation resistant  
532 antibody fragment.

533

534

## 535 **Materials and Methods**

536

### 537 **Fab A33 homology model**

538 The homology model of wild-type Fab A33 was built from the crystal structure of human  
539 germline antibody 5-51/O12 (PDB ID: 4KMT) and the amino-acid sequence of Fab A33 (Fig. S1)  
540 [46,47]. The C226S heavy-chain variant was used to avoid the formation of linked Fab dimers.  
541 We used the Rosetta method “minirosetta”, as detailed in previous works [48].

542

### 543 **Molecular dynamics simulations**

544 Molecular dynamic (MD) simulations on the Fab A33 homology model were conducted in  
545 Gromacs v5.0 [49]. MD simulations were carried out at neutral pH and room temperature (pH 7.0  
546 and 300 K) and under two stresses, low pH (pH 3.5 and pH 4.5 at 300 K) and high temperature  
547 (pH 7.0 at 340 K and 380 K). Many high temperature simulations are performed at relatively high  
548 temperatures (e.g. 500 K), to achieve complete denaturation of the protein, however, in this case,  
549 we aim to partially unfold Fab A33 and detect the regions prone to early unfolding. Simulations  
550 were carried out using the OPLS-AA/L all-atom force field [50]. The Fab PDB file was first  
551 converted to a topology file with its five (four intra-chain and one inter-chain) disulfide bonds  
552 retained. The protonation state of each residue was entered manually, and these were determined

553 at each pH using the PDB2PQR server, which performed the pKa calculations by PropKa [51].  
554 This gave the following total charges: +9 (pH 7.0), +18 (pH 4.5) and +35 (pH 3.5). The Fab A33  
555 structure was centered in a cubic box with a layer of water up to at least 10.0 Å from the protein  
556 surface. The box was solvated with SPC/E water molecules, Cl<sup>-</sup> added to neutralize the net  
557 charges, and NaCl added to an ionic strength of 50 mM for all simulations. The system was energy  
558 minimized using the steepest descent algorithm (2000 steps) followed by the conjugate gradient  
559 method (5000 steps). The solvent and ions around the protein were equilibrated in position-  
560 restricted simulations for 100 ps under NVT ensemble to stabilize at the specified temperature,  
561 and then at 100 ps under NPT ensemble to stabilize at atmospheric pressure. Lastly, MD  
562 simulations were carried out for 50 ns in triplicates under the five conditions (pH 7.0 and 300 K;  
563 pH 4.5 and 300 K; pH 3.5 and 300 K; pH 7.0 and 340 K; pH 7.0 and 380 K). Jobs were submitted  
564 to the UCL Legion High Performance Computing Facility. The time step of the simulations was  
565 set to 2 fs and trajectories were saved every 10 ps.

566

### 567 **Analysis of MD trajectories**

568 MD trajectories were saved reduced, every 0.2 ns (total of 250 frames). Interface contacts  
569 over simulation time were calculated using the native contacts extension of the visual molecular  
570 dynamics (VMD) program [52]. A cutoff distance of 4 Å was used in the calculations. Variable  
571 domain contacts ( $V_L$ - $V_H$ ) were calculated between residues 1-108 ( $V_L$ ) and 215-334 ( $V_H$ ). Constant  
572 domain contacts ( $C_L$ - $C_{H1}$ ) were calculated between residues 109-214 ( $C_L$ ) and 335-442 ( $C_{H1}$ ).  
573 RMSD of individual domains during the simulations were calculated using the RMSD trajectory  
574 tool in VMD. All the structures of the trajectory were first aligned and the RMSD was calculated  
575 (no hydrogens included). Domains were  $V_L$  (1-108),  $V_H$  (215-334),  $C_L$  (109 to 214) and  $C_{H1}$  (335  
576 to 429). Averages and SEM of three independent repeats are shown. Structural alignments of the  
577 last 30 ns of the trajectories were also performed using VMD. Secondary structure (SS)  
578 assignments of each residue along the trajectory were done using the DSSP module [53,54]. To



579 analyze the loss in  $\beta$ -strand structure, we monitored the percentage of  $\beta$ -sheet SS per residue.  
580 These values were summed for each of the 32  $\beta$ -strands in Fab A33 and differences were  
581 calculated between the unfolding simulations and the reference simulations (pH 7 and 300 K).  
582 Lastly, salt bridges were calculated along the trajectories using VMD and a cutoff distance  
583 between O and N groups of 3.2 Å. From these, the occurrence (%) of each salt bridge during the  
584 simulation was calculated, and averaged for the three independent repeats at each condition.

585

### 586 **Mutational study and $\Delta\Delta G$ calculations by FoldX and Rosetta**

587 The effect of mutations on the stability of Fab A33 was studied using FoldX ([foldx.crg.es](http://foldx.crg.es))  
588 [26] and the Rosetta method “ddg\_monomer” ([www.rosettacommons.org](http://www.rosettacommons.org)) [27]. Both tools  
589 predicted the difference in folding free energy,  $\Delta\Delta G$ , between the protein carrying a point mutation  
590 and the wildtype. Each of the 442 residues in the Fab A33 were mutated to the other 19  
591 possibilities, totaling 8398 single mutants. FoldX was used as a plugin in the graphical interface  
592 YASARA [55]. The “Repair” command was used first to energy minimize the homology model of  
593 Fab A33, by rearranging the amino acid side chains. Next, the “BuildModel” command was used  
594 to introduce the point mutations, optimize the structure of the new protein variant, and calculate  
595 the stability change upon mutation. The Rosetta “ddg\_monomer” method was used, where an  
596 example of mutation and option files, listing the parameters of the executable, can be seen in  
597 previous work [48]. Jobs were submitted to the UCL Legion High-Performance Computing Facility.

598

### 599 **Packing Density**

600 Occluded surface (OS) program was used to calculate the atomic packing of Fab A33  
601 [30,31]. The occluded surface packing (OSP) values are useful for identifying regions of loose  
602 packing in a protein. OSP value for each residue are calculated from the collection of extended  
603 normals (ray-lengths) that extend outward from the molecular surface until they intersect

604 neighboring van der Waals surface. Analysis of these normals, their respective lengths and the  
605 surface area involved in the interaction, defines the packing of each atom in the protein.

606

### 607 **Sequence Entropy of Fab sequences**

608 Fab sequences were retrieved from the Protein Data Bank (PDB) [32], totaling one  
609 hundred light chains and one hundred heavy chains. For light chains, kappa ( $\kappa$ ) and lambda ( $\lambda$ )  
610 chains were included. For  $\kappa$  light chains,  $\lambda$  light chains and heavy chains, sequences from the  
611 species human and mouse were used. Sequence alignment and calculation of the sequence  
612 entropy for each residue were calculated using Bioedit [33]. The maximum entropy for 21 possible  
613 amino acids (including stop codon) is 3.04 and zero represents a fully conserved residue.

614

### 615 **Aggregation-prone regions (APR) predictions**

616 Aggregation prone regions (APR) of Fab A33 were predicted using PASTA 2.0 [35],  
617 TANGO [36], AGGRESCAN [37] and MetAmyl [38], using the protein sequence as input. The  
618 regions in which three out of the four software identified an APR were selected, resulting in seven  
619 APRs. Amylpred2 consensus tool was used to confirm the presence of these APRs [45]. To  
620 calculate the solvent accessible surface area (SASA) of each APR during the trajectories, the  
621 average area per residue over the trajectory was calculated first, using gromacs analysis tool  
622 “sasa”, then summed for each APR.

623

624

625

626

627

628

629

630

631 **ACKNOWLEDGMENTS**

632 We thank the Engineering and Physical Sciences Research Council (EPSRC) Centre for Doctoral

633 Training in Emergent Macromolecular Therapies (EP/L015218/1) (N.C.C.), the EPSRC Future

634 Targeted Healthcare Manufacturing Hub (EP/P006485/1, EP/I033270/1) (N.C.), and EPSRC

635 EP/N025105/1 (C.Z.).

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657 **REFERENCES**

- 658 1. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. *MAbs*.  
659 2015;7(1):9–14.
- 660 2. Carter PJ, Lazar GA. Next generation antibody drugs: Pursuit of the “high-hanging fruit.”  
661 *Nat Rev Drug Discov*. 2018;17:197–223.
- 662 3. Nelson AL. Antibody fragments: hope and hype. *MAbs*. 2010;2(1):77–83.
- 663 4. Enever C, Batuwangala T, Plummer C, Sepp A. Next generation immunotherapeutics-  
664 honing the magic bullet. *Curr Opin Biotechnol*. 2009;20(4):405–11.
- 665 5. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein  
666 pharmaceuticals: An update. *Pharm Res*. 2010;27(4):544–75.
- 667 6. Wang W, Nema S, Teagarden D. Protein aggregation-pathways and influencing factors.  
668 *Int J Pharm*. 2010;390(2):89–99.
- 669 7. Wang W. Protein aggregation and its inhibition in biopharmaceutics. *Int J Pharm*.  
670 2005;289(1–2):1–30.
- 671 8. Chiti F, Dobson CM. Amyloid formation by globular proteins under native conditions. *Nat*  
672 *Chem Biol*. 2009;5:15–22.
- 673 9. Neudecker P, Robustelli P, Cavalli A, Walsh P, Lundström P, Zarrine-Afsar A, et al.  
674 Structure of an intermediate state in protein folding and aggregation. *Science*.  
675 2012;336(6079):362–6.
- 676 10. Canet D, Last AM, Tito P, Sunde M, Spencer A, Archer DB, et al. Local cooperativity in  
677 the unfolding of an amyloidogenic variant of human lysozyme. *Nat Struct Biol*.  
678 2002;9:308–15.
- 679 11. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. A transient expansion of the  
680 native state precedes aggregation of recombinant human interferon- $\gamma$ . *Proc Natl Acad*

- 681 Sci. 1998;95(24):14142–6.
- 682 12. Chakroun N, Hilton D, Ahmad SS, Platt GW, Dalby PA. Mapping the Aggregation Kinetics  
683 of a Therapeutic Antibody Fragment. *Mol Pharm.* 2016;13(2):307–19.
- 684 13. De Baets G, Schymkowitz J, Rousseau F. Predicting aggregation-prone sequences in  
685 proteins. *Essays Biochem.* 2014;56:41–52.
- 686 14. Codina N, Hilton D, Zhang C, Chakroun N, Ahmad SS, Perkins SJ, et al. An Expanded  
687 Conformation of an Antibody Fab Region by X-Ray Scattering, Molecular Dynamics and  
688 smFRET Identifies an Aggregation Mechanism. *J Mol Biol.* 2019;431(7):1409–25.
- 689 15. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous  
690 solution: Mechanism and driving forces in nonnative protein aggregation. *Pharm Res.*  
691 2003;20(9):1325–36.
- 692 16. Lindorff-Larsen K, Trbovic N, Maragakis P, Piana S, Shaw DE. Structure and dynamics of  
693 an unfolded protein examined by molecular dynamics simulation. *J Am Chem Soc.*  
694 2012;134(8):3787–91.
- 695 17. Rocco AG, Mollica L, Ricchiuto P, Baptista AM, Gianazza E, Eberini I. Characterization of  
696 the protein unfolding processes induced by urea and temperature. *Biophys J.*  
697 2008;94(6):2241–51.
- 698 18. Salimi NL, Ho B, Agard DA. Unfolding simulations reveal the mechanism of extreme  
699 unfolding cooperativity in the kinetically stable  $\alpha$ -lytic protease. *PLoS Comput Biol.*  
700 2010;6(2):e1000689.
- 701 19. Settanni G, Fersht AR. High temperature unfolding simulations of the TRPZ1 peptide.  
702 *Biophys J.* 2008;94(11):4444–53.
- 703 20. Collu F, Spiga E, Chakroun N, Rezaei H, Fraternali F. Probing the early stages of prion  
704 protein (PrP) aggregation with atomistic molecular dynamics simulations. *Chem*  
705 *Commun.* 2018;54(57):8007–10.
- 706 21. Patel D, Kuyucak S. Computational study of aggregation mechanism in human

- 707 lysozyme[D67H]. PLoS One. 2017;12(5):1–17.
- 708 22. Buck PM, Kumar S, Singh SK. Insights into the potential aggregation liabilities of the b12  
709 Fab fragment via elevated temperature molecular dynamics. Protein Eng Des Sel.  
710 2013;26(3):195–206.
- 711 23. Su JG, Zhang X, Han XM, Zhao SX, Li CH. The intrinsic dynamics and unfolding process  
712 of an antibody fab fragment revealed by elastic network model. Int J Mol Sci.  
713 2015;16(12):29720–31.
- 714 24. Wang T, Duan Y. Probing the stability-limiting regions of an antibody single-chain variable  
715 fragment: a molecular dynamics simulation study. Protein Eng Des Sel. 2011;24(9):649–  
716 57.
- 717 25. Kortkhonjia E, Brandman R, Zhou JZ, Voelz VA, Chorny I, Kabakoff B, et al. Probing  
718 antibody internal dynamics with fluorescence anisotropy and molecular dynamics  
719 simulations. MAbs. 2013;5(2):306–22.
- 720 26. Zhang Z, Wang L, Gao Y, Zhang J, Zhenirovskyy M, Alexov E. Predicting folding free  
721 energy changes upon single point mutations. Bioinformatics. 2012;28(5):664–71.
- 722 27. Kellogg EH, Leaver-Fay A, Baker D. Role of conformational sampling in computing  
723 mutation-induced changes in protein structure and stability. Proteins. 2011;79(3):830–8.
- 724 28. Wijma HJ, Floor RJ, Jekel PA, Baker D, Marrink SJ, Janssen DB. Computationally  
725 designed libraries for rapid enzyme stabilization. Protein Eng Des Sel. 2014;27(2):49–58.
- 726 29. Buß O, Rudat J, Ochsenreither K. FoldX as Protein Engineering Tool: Better Than  
727 Random Based Approaches? Comput Struct Biotechnol J. 2018;16:25–33.
- 728 30. Pattabiraman N, Ward KB, Fleming PJ. Occluded molecular surface: analysis of protein  
729 packing. J Mol Recognit. 1995;8(6):334–44.
- 730 31. Fleming PJ, Richards FM. Protein packing: dependence on protein size, secondary  
731 structure and amino acid composition. J Mol Biol. 2000;299(2):487–98.
- 732 32. Rose PW, Bi C, Bluhm WF, Christie CH, Dimitropoulos D, Dutta S, et al. The RCSB

- 733 Protein Data Bank: new resources for research and education. *Nucleic Acids Res.*  
734 2013;41(D1):D475–82.
- 735 33. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis  
736 program for Windows 95/98/NT. *Nucleic Acids Symp Ser.* 1999;41:95–8.
- 737 34. Elgert KD. Antibody structure and function. In: *Immunology: Understanding the Immune*  
738 *System.* John Wiley & Sons; 1998. p. 58–78.
- 739 35. Walsh I, Seno F, Tosatto SCE, Trovato A. PASTA 2.0: an improved server for protein  
740 aggregation prediction. *Nucleic Acids Res.* 2014;42(W1):301–7.
- 741 36. Fernandez-Escamilla A-M, Rousseau F, Schymkowitz J, Serrano L. Prediction of  
742 sequence-dependent and mutational effects on the aggregation of peptides and proteins.  
743 *Nat Biotechnol.* 2004;22(10):1302–6.
- 744 37. Conchillo-Solé O, de Groot NS, Avilés FX, Vendrell J, Daura X, Ventura S.  
745 AGGRESCAN: a server for the prediction and evaluation of “hot spots” of aggregation in  
746 polypeptides. *BMC Bioinformatics.* 2007;8(1):65.
- 747 38. Emily M, Talvas A, Delamarche C. MetAmyl: A METa-predictor for AMYloid proteins.  
748 *PLoS One.* 2013;8(11).
- 749 39. Garbuzynskiy SO, Lobanov MY, Galzitskaya O V. FoldAmyloid: a method of prediction of  
750 amyloidogenic regions from protein sequence. *Bioinformatics.* 2010;26(3):326–32.
- 751 40. Maurer-Stroh S, Debulpaep M, Kuemmerer N, de la Paz ML, Martins IC, Reumers J, et  
752 al. Exploring the sequence determinants of amyloid structure using position-specific  
753 scoring matrices. *Nat Methods.* 2010;7(3):237–42.
- 754 41. Zambrano R, Jamroz M, Szczasiuk A, Pujols J, Kmiecik S, Ventura S. AGGRESCAN3D  
755 (A3D): server for prediction of aggregation properties of protein structures. *Nucleic Acids*  
756 *Res.* 2015;43(W1):W306–13.
- 757 42. Sankar K, Krystek SR, Carl SM, Day T, Maier JKX. AggScore: Prediction of aggregation-  
758 prone regions in proteins based on the distribution of surface patches. *Proteins.*

- 759 2018;86(11):1147–56.
- 760 43. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins  
761 with enhanced stability. *Proc Natl Acad Sci*. 2009;106(29):11937–42.
- 762 44. Van Durme J, De Baets G, Van Der Kant R, Ramakers M, Ganesan A, Wilkinson H, et al.  
763 Solubis: A webserver to reduce protein aggregation through mutation. *Protein Eng Des*  
764 *Sel*. 2016;29(8):285–9.
- 765 45. Tsolis AC, Papandreou NC, Iconomidou VA, Hamodrakas SJ. A Consensus Method for  
766 the Prediction of “Aggregation-Prone” Peptides in Globular Proteins. *PLoS One*.  
767 2013;8(1):1–6.
- 768 46. Chivian D, Baker D. Homology modeling using parametric alignment ensemble  
769 generation with consensus and energy-based model selection. *Nucleic Acids Res*.  
770 2006;34(17):1–18.
- 771 47. Raman S, Vernon R, Thompson J, Tyka M, Pei J, Kim D, et al. Structure prediction for  
772 CASP8 with all-atom refinement using Rosetta. *Proteins*. 2009;77(Suppl 9):89–99.
- 773 48. Zhang C, Samad M, Yu H, Chakroun N, Hilton D, Dalby PA. Computational Design to  
774 Reduce Conformational Flexibility and Aggregation Rates of an Antibody Fab Fragment.  
775 *Mol Pharm*. 2018;15(8):3079–92.
- 776 49. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High  
777 performance molecular simulations through multi-level parallelism from laptops to  
778 supercomputers. *SoftwareX*. 2015;1–2:19–25.
- 779 50. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and  
780 reparametrization of the OPLS-AA force field for proteins via comparison with accurate  
781 quantum chemical calculations on peptides. *J Phys Chem B*. 2001;105(28):6474–87.
- 782 51. Li H, Robertson AD, Jensen JH. Very fast empirical prediction and rationalization of  
783 protein pK<sub>a</sub> values. *Proteins Struct Funct Genet*. 2005;61(4):704–21.
- 784 52. Humphrey W, Dalke A, Klaus S. VMD: Visual Molecular Dynamics. *J Mol Graph*.



- 785           1996;14(1):33–8.
- 786   53.   Touw WG, Baakman C, Black J, Te Beek TAH, Krieger E, Joosten RP, et al. A series of  
787           PDB-related databanks for everyday needs. *Nucleic Acids Res.* 2015;43(D1):D364–8.
- 788   54.   Kabsch W, Sander C. Dictionary of protein secondary structure: Pattern recognition of  
789           hydrogen-bonded and geometrical features. *Biopolymers.* 1983;22(12):2577–637.
- 790   55.   van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, Rousseau F. A graphical  
791           interface for the FoldX forcefield. *Bioinformatics.* 2011;27(12):1711–2.
- 792
- 793
- 794
- 795
- 796
- 797
- 798
- 799
- 800
- 801
- 802
- 803
- 804
- 805
- 806
- 807
- 808
- 809
- 810

811

812

### 813 **Supporting information captions**

814

815 **Fig S1. Fab A33 sequence.** Fab A33 amino acid sequence separated by domains ( $V_L$ ,  $C_L$ ,  $V_H$ ,  
816  $C_H1$  and hinge region). The six CDRs in the  $V_L$  and  $V_H$  domains are highlighted in red.

817

818 **Table S1. Residues located in the interface between light and heavy chains in Fab A33.**

819

820 **Fig S2. All protein RMSD and radius of gyration ( $R_g$ ) with simulation time.** A, B) RMSD of  
821 the whole protein with simulation time for different A) pHs and B) temperatures, values as labelled.  
822 In all cases, the average of three independent simulations is shown with the SEM as error. C, D)  
823 Radius of gyration ( $R_g$ ) of Fab A33 with simulation time for different A) pHs and B) temperatures,  
824 values as labelled. In all cases, the average of three independent simulations is shown with the  
825 SEM as error.

826

827 **Fig S3. Secondary structure (SS) of each residue in Fab A33 with simulation time,**  
828 **calculated using DSSP.** Representative SS evolution are shown for A) pH 7.0 and 300K, B) pH  
829 3.5 and 300K and C) pH 7.0 and 380 K, secondary structure type as indicated in the legend.

830

831 **Fig S4. Loss of secondary structure for each of the 32  $\beta$ -strands of Fab A33.** A, B) Strand  
832 order shown by lettering (A-G) for variable and constant domains, respectively. C, D) Percentage  
833 increase/decrease in  $\beta$ -strand secondary structure for each strand in Fab during the simulations,  
834 respect to pH 7.0 and 300 K, for: C) pH 4.5 and 300 K, D) pH 7.0 and 340 K. Error bars are the  
835 same and equal for positive and negative values.

836

837 **Fig S5. Salt Bridge analysis for simulations at pH 4.5 at 300 K, and pH 7.0 at 340 K.** A, B)  
838 Salt bridges formed during the simulation time for representative MD simulations at A) pH 4.5 and  
839 300 K, B) pH 7.0 and 340 K. Presence of a salt bridge is indicated in white and absence in black.  
840 C, D) List of salt bridges and its occurrence for simulations at A) pH 4.5 and 300 K, B) pH 7.0 and  
841 340 K. Values shown are the average of three independent simulations with their SEM as error.  
842 The more persistent salt bridges are highlighted for pH 4.5 (red) and for high temperature 340 K  
843 (blue). E, F) The more persistent salt bridges are mapped into the Fab A33 structure.

844

845 **Fig S6. Stabilizing mutations predicted by FoldX and Rosetta. Correlation between FoldX**  
846 **and Rosetta predictions.** Mutations predicted by both software to be most stabilizing are shown  
847 in magenta and highlighted in a gray square on the bottom left. Mutations predicted only by FoldX  
848 to be stabilizing are shown in green and mutations predicted only by Rosetta in yellow.

849

850 **Table S2. List of the most stabilizing mutations identified by FoldX and Rosetta-ddG.**  
851 Mutation and  $\Delta\Delta G$  of the 25 most stabilizing mutations predicted by FoldX and Rosetta.

852

853 **Fig S7. Normals used to calculate the packing of each atom in Fab A33 using occluded**  
854 **surface software.** To calculate the occluded surface packing (OSP) value for each residue,  
855 normals that extend from the surface outward until they intersect a neighboring van der Waals  
856 surface are used. The normals used to calculate the OSP value of the inter-domain residues  
857 identified by FoldX and Rosetta (S176, N137, S397, T180, and S395), are shown.

858

859 **Table S3. Packing indicated by the occluded surface packing (OSP) value of the residues**  
860 **located in  $\beta$ -strands within domain interfaces ( $V_L$ - $V_H$  and  $C_L$ - $C_H1$ ) of Fab A33 homology**  
861 **model.** OSP values were calculated using the occluded surface software.

862 \*, residues identified by FoldX and Rosetta in the constant domain interface that can be stabilized

863 further.

864

865 **Fig S8. Sequence entropy of Fab sequences.** (A) Entropy (Hx) of one hundred Fab light chains,  
866 including  $\kappa$  and  $\lambda$  light chains. (B) Entropy (Hx) of one hundred Fab heavy chains. Light and heavy  
867 chains are from human and mouse species. Alignment and entropy calculation were done with  
868 Bioedit. Variable domains are indicated with a (V) and constant domains with a (C), separated by  
869 a vertical line. CDRs are indicated in red.

870

871 **Fig S9. Aggregation prone regions (APR) in Fab A33.** A) The normalised aggregation  
872 propensity for each residue in Fab A33 was predicted using PASTA 2.0, TANGO, AGGRESCAN  
873 and MetAmyl software, each being colour-coded as shown in the legend. Aggregation-prone  
874 sequences where three of the four software agreed were selected, and highlighted with an  
875 asterisk. Amylpred2 consensus tool was also used to confirm the identification of those APRs,  
876 indicated in red on the top. B) Using the native Fab A33 homology model, regions with greater  
877 aggregation propensities are shown in red and reduced propensities in blue.

878




Figure 1




Figure 2




Figure 3




Figure 4








Figure 5





Figure 6




Figure 7





Figure 8